There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| Ask | Qty | Orders |
|---|---|---|
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
Annual Revenue,rose 13.77%, in the last year to ₹22,903.72 Cr. Its sector's average revenue growth for the last fiscal year was 10.53%.Annual Net Profit,rose 71.41% in the last year to ₹3,281.62 Cr. Its sector's average net profit growth for the last fiscal year was 36.7%.Price to Earning Ratio,is 25.23, lower than its sector PE ratio of 41.8.
Founded in 1968 by Dr. Desh Bandhu Gupta, Lupin Limited is a Mumbai‑headquartered, innovation‑led transnational pharmaceutical company. Incorporated in 1983, the company develops, manufactures and markets a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) . Lupin has significant presence across Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro‑Intestinal, Anti‑Infectives and Nonsteroidal Anti‑Inflammatory Drug therapies, and is a global leader in Anti‑TB and Cephalosporins . Its products are distributed in over 100 markets, with strong presence across North America, EMEA, LATAM, APAC and India; operations span 112 countries as per the Business Responsibility and Sustainability Report . Manufacturing locations are spread across India, USA, Mexico and Brazil, with 15 manufacturing sites and seven research centres supporting global supply and innovation fileciteturn5 .
As on March 31, 2025, Lupin had 32 subsidiaries worldwide (do not list names) and one joint venture, reflecting its diversified operating footprint and corporate structure . Key milestones in the latest year included 41 product filings, 52 approvals and 87 patents secured, underscoring the company’s focus on complex generics and specialty portfolios across major markets .
– North America contributed 36 Per cent to revenues in FY25, affirming Lupin’s scale in the U.S. generics market .
– India contributed 34 Per cent to global turnover in FY25 .
– Other Developed Markets (Europe and Australia) contributed 11 Per cent of global revenues .
– Emerging Markets contributed 11 Per cent of global revenues .
– Domestic vs. International: On a standalone basis, exports comprised 53.9 Per cent of total sales in FY25 .
– Manju D. Gupta – Chairperson
– Vinita Gupta – Chief Executive Officer
– Nilesh D. Gupta – Managing Director
– Ramesh Swaminathan – Executive Director, Global CFO, Head of IT and API Plus SBU
– Amit Kumar Gupta – Company Secretary
– Portfolio and market expansion: Lupin acquired Eli Lilly’s Huminsulin and three diabetes products from Boehringer Ingelheim in India; it also acquired two specialty brands from Sanofi (Aarane in Germany and Nalcrom in Canada and the Netherlands) .
– Biologics progress: The company launched its first biosimilar, Rymti, in Canada and filed for Ranibizumab in the EU .
– Subsidiary additions: Lupin incorporated Lupin Lanka (Private) Limited in Sri Lanka and Lupin NZ Limited in New Zealand, expanding its presence in South Asia and Oceania .
– Pipeline momentum: In FY25, Lupin filed 41 products and received 52 approvals; 87 patents were secured, highlighting continued R&D intensity across inhalation, injectables, ophthalmic and oral segments .
– Regional performance highlights: North America sales grew 15.9 Per cent; Other Developed Markets rose 23.4 Per cent; Emerging Markets increased 6.8 Per cent, supported by differentiated portfolios and supply chain agility .
Lupin develops and sells branded and generic medicines, biosimilars and APIs across major therapy areas including cardiovascular, diabetes, respiratory, CNS and GI, and is a global leader in Anti‑TB and Cephalosporins . Its portfolio spans generics, complex generics, specialty medicines and biotechnology products .
The company serves 112 countries, with manufacturing across India, USA, Mexico and Brazil; it operates 15 manufacturing sites and seven R&D centres fileciteturn5 .
As on March 31, 2025, Lupin had 32 subsidiaries and one joint venture . Recent highlights include acquisitions in diabetes and specialty brands, the launch of biosimilar Rymti in Canada, filings in the EU, and strong R&D output with 41 filings and 52 approvals in FY25 .
